At 17.3% CAGR, the Asia Pacific Cell and Gene Therapy Manufacturing Services Market is Projected to be worth US$ 3,613.18 million by 2030, says Business Market Insights

According to Business Market Insights research, the Asia Pacific cell and gene therapy manufacturing services market was valued at US$ 1,007.42 million in 2022 and is expected to reach US$ 3,613.18 million by 2030, registering a CAGR of 17.3% from 2022 to 2030. Strategic initiatives by companies and automation of cell and gene therapy manufacturing services are among the critical factors attributed to the Asia Pacific cell and gene therapy manufacturing services market expansion.               

Companies operating in the Asia Pacific cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

•             In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

•             In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

•             In March 2022, Cellevolve Bio partnered with Seattle Children’s Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children’s Cure Factory facility to conduct early clinical GMP research on new CARs.

•             In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist’s antibody libraries with Kriya’s proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya’s gene therapy technology.

Thus, these strategic initiatives create significant growth opportunities in the Asia Pacific cell and gene therapy manufacturing services market.  

On the contrary, high cost of cell and gene therapy manufacturing hurdles the growth of Asia Pacific cell and gene therapy manufacturing services market.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 68.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 687.78 million. It is projected to garner US$ 2,498.47 million by 2030 to expand at 17.5% CAGR during 2022–2030. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. The cancer segment held 56.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 566.93 million. It is projected to garner US$ 2,164.42 million by 2030 to expand at 18.2% CAGR during 2022–2030.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held 63.1% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 636.16 million. It is projected to garner US$ 2,404.04 million by 2030 to expand at 18.1% CAGR during 2022–2030.  

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). The pharmaceutical and biotechnology companies segment held 78.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022, amassing US$ 788.69 million. It is projected to garner US$ 2,850.25 million by 2030 to expand at 17.4% CAGR during 2022–2030.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 35.3% share of Asia Pacific cell and gene therapy manufacturing services market in 2022. It was assessed at US$ 355.32 million in 2022 and is likely to hit US$ 1,338.17 million by 2030, exhibiting a CAGR of 18.0% during 2022–2030.  

Key players operating in the Asia Pacific cell and gene therapy manufacturing services market are Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co LtdĀ, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com